À̼¼ÈÆ ¸íÀÇ

Æó¾Ï À¯Àüü ¸ÂÃãÄ¡·á¿Í ¸é¿ªÇ×¾ÏÁ¦ ¿¬±¸ ¼±µµ

À̼¼ÈÆ ¸íÀÇ

  • ¼Ò ¼Ó
    »ï¼º¼­¿ïº´¿ø
  • Áø·á°ú
    Ç÷¾×Á¾¾ç³»°ú
  • Àü¹®ºÐ¾ß
    Æó¾Ï, µÎ°æºÎ¾Ï

À̼¼ÈÆ ±³¼ö´Â Æó¾Ï°ú µÎ°æºÎ¾Ï ºÐ¾ßÀÇ Ç×¾Ï È­Çпä¹ý ¹× ¸ÂÃã Ä¡·á¸¦ ¼±µµÇÏ´Â ¼¼°èÀûÀÎ ±ÇÀ§ÀÚÀÌ´Ù. ƯÈ÷ ¾Ï¼¼Æ÷ÀÇ À¯ÀüÀû Ư¼ºÀ» ºÐ¼®ÇØ È¯ÀÚ °³°³Àο¡°Ô °¡Àå ÀûÇÕÇÑ ¾à¹°À» ã¾Æ³»´Â 'Á¤¹Ð ÀÇ·á' ¿¬±¸¿¡ ÁýÁßÇÏ¿©Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®(NGS)À» ÅëÇØ Ÿ°Ù À¯ÀüÀÚ¸¦ ¹ß±¼Çϰí, À̸¦ ¹ÙÅÁÀ¸·Î ÇÑ ÀÓ»ó½ÃÇèÀ» ÁÖµµÇÏ¸ç ³­Ä¡¼º Æó¾Ï ȯÀڵ鿡°Ô »õ·Î¿î Ä¡·á ±âȸ¸¦ Á¦°øÇϰí ÀÖ´Ù. ¶ÇÇÑ Â÷¼¼´ë ¸é¿ªÇ×¾ÏÁ¦¿Í ¾×ü »ý°Ë ¿¬±¸¿¡¼­µµ µ¶º¸ÀûÀÎ ¼º°ú¸¦ ³»°í ÀÖ´Ù. 2024³â¿¡´Â ÀüÀ̼º Æó¾Ï ȯÀÚÀÇ ¸é¿ªÇ×¾ÏÁ¦ ¹ÝÀÀÀ» ¿¹ÃøÇÏ´Â »õ·Î¿î ¹ÙÀÌ¿À¸¶Ä¿ ¿¬±¸¸¦ ±¹Á¦ÀûÀÎ ÇмúÁö¿¡ ¹ßÇ¥Çϸç ÁÖ¸ñ¹Þ¾Ò´Ù. ȯÀÚÀÇ °íÅëÀ» ´ú¾îÁÖ±â À§ÇÑ ÃÖ÷´Ü Ç×¾Ï Àü·« ¼ö¸³¿¡ ¸ÅÁøÇϸç, ¿¬±¸ ¼º°ú¸¦ ½ÇÁ¦ Áø·á ÇöÀå¿¡ ºü¸£°Ô Àû¿ëÇÏ´Â ÀÇ»çÀÌÀÚ ¿¬±¸ÀÚÀÌ´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • ¼­¿ï´ë ÀÇ´ë Çлç
  • ¼­¿ï´ë ÀÇ´ë ¼®»ç
  • ¼­¿ï´ë ÀÇ´ë ¹Ú»ç

ÁÖ¿ä°æ·Â

Work Experience

ÇÐȸȰµ¿

Academic activities
  • 2013 ~ ÇöÀç´ëÇÑÀ¯ÀüüÇÐȸ/È«º¸À§¿øÀå(¿ªÀÓ), 2014µ¿°èÇмúÀ§¿ø(¿ªÀÓ), 2015µ¿°è±âȹÀ§¿ø(¿ªÀÓ)
  • 2012 ~ ÇöÀç»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ(KSBMB)/2013Á¤±âÇмúÀ§¿ø(¿ªÀÓ)
  • 2011 ~ ÇöÀç ´ëÇѽŰæÁ¾¾çÇÐȸ/°¨»ç, º¸Çè¹×´ë¿ÜÇù·ÂÀ§¿øÀå(¿ªÀÓ), µî·ÏÀ§¿øÀå(¿ªÀÓ), ´ÙÇÐÁ¦¼ÒÀ§¿øÀå(¿ªÀÓ), PRCÀ§¿ø, ´ÙÇÐÁ¦À§¿øÈ¸ µî·ÏÃ¥ÀÓÀ§¿ø
  • 2011 ~ ÇöÀç½Å°æÁ¾¾çÇÐȸ(SNO)/ȸ¿ø
  • 2010 ~ ÇöÀç´ëÇѵΰæºÎÁ¾¾çÇÐȸ/ÆíÁýÀ§¿ø(¿ªÀÓ)
  • 2008 ~ ÇöÀç±¹Á¦Æó¾ÏÇÐȸ(IASLC)/ȸ¿ø
  • 2007 ~ ÇöÀç´ëÇÑÆó¾ÏÇÐȸ/ÇмúÀ§¿ø(¿ªÀÓ), ±âȹÀ§¿ø(¿ªÀÓ)
  • 2007 ~ ÇöÀç¹Ì±¹¾Ï¿¬±¸ÇÐȸ(AACR)/ȸ¿ø
  • 2005 ~ ÇöÀç´ëÇÑÁ¾¾ç³»°úÇÐȸ/ÇмúÀ§¿øÀå, ´ÙÇÐÁ¦À§¿øÀå(¿ªÀÓ), ±³À°À§¿ø(¿ªÀÓ), ÆíÁýÀ§¿ø(¿ªÀÓ), ÇмúÀ§¿ø(¿ªÀÓ), ±âȹÀ§¿ø(¿ªÀÓ)
  • 2003 ~ ÇöÀç ¹Ì±¹ÀÓ»ó¾ÏÇÐȸ(ASCO)/ȸ¿ø
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 0°Ç
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA
¹ßÇ¥³âµµ 2025 ¹ßÇ¥Áö Journal of Thoracic Oncology
Á¦ ¸ñ Systematic dissection of tumor-normal single-cell ecosystems across a thousand tumors of 30 cancer types
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö Nature Communications
Á¦ ¸ñ Intracellular Adhesion Molecule-1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8+ T Cells
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Advanced Science
Á¦ ¸ñ Systematic analysis of Mendelian disease-associated gene variants reveals new classes of cancer-predisposing genes
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Genome Medicine
Á¦ ¸ñ Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer
¹ßÇ¥³âµµ 2022 ¹ßÇ¥Áö Journal of Clinical Oncology
Á¦ ¸ñ High-Resolution Profiling of Lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities
¹ßÇ¥³âµµ 2022 ¹ßÇ¥Áö Cancer Research
Á¦ ¸ñ Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice
¹ßÇ¥³âµµ 2021 ¹ßÇ¥Áö Nature Microbiology

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

»ï¼º¼­¿ïº´¿ø

»ó±ÞÁ¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1599-3114

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

»ï¼º¼­¿ïº´¿øÀº 1994³â °³¿øÇÑ Á¾ÇÕ ÀÇ·á±â°üÀ¸·Î º»°ü, º°°ü, ¾Ïº´µ¿À¸·Î ±¸¼ºµÅ ÀÖÀ¸¸ç ¾à 1979º´»ó ±Ô¸ð¸¦ °®Ãß°í ÀÖ´Ù. 2014³â ¾ç¼ºÀÚ Ä¡·á¼¾ÅÍ, 2015³â ¹Ì·¡ ÀÇÇаüÀÌ ¿Ï°øµÆÀ¸¸ç, ÇöÀç 2019³â ¿Ï°øÀ» ¸ñÇ¥·Î Åë¿øÄ¡·á¼¾ÅÍ °ø»ç¸¦ ÁøÇàÇϰí ÀÖ´Ù. ȯÀÚ ÇູÀ» À§ÇÑ ÀÇ·á Çõ½Å ±¸Çö, º´¿ø-¿¬±¸¼Ò-Çб³-±â¾÷ü¸¦ ¿¬°áÇÏ´Â ¹ÙÀÌ¿À ÇコÄÉ¾î ¿¬±¸ ¹× ¿¬°è »ê¾÷ÀÇ ±Û·Î¹ú Çãºê¸¦ ¸ñÇ¥·Î ÇÑ´Ù.

»ï¼º¼­¿ïº´¿ø À̹ÌÁö

¼­¿ïƯº°½Ã °­³²±¸ ÀÏ¿ø·Î 81

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä